These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19203543)

  • 1. First-in-man and first-of-class-in-man clinical trials in oncology.
    Mross K
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):68-70. PubMed ID: 19203543
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
    Ji Y; Jin JY; Hyman DM; Kim G; Suri A
    Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
    [No Abstract]   [Full Text] [Related]  

  • 5. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Am Soc Clin Oncol Educ Book; 2015; ():3-8. PubMed ID: 25993134
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
    Seegers V; Chevret S; Resche-Rigon M
    Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-stage dose finding for cytostatic agents in phase I oncology trials.
    Yin G; Zheng S; Xu J
    Stat Med; 2013 Feb; 32(4):644-60. PubMed ID: 22855354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology.
    Altzerinakou MA; Paoletti X
    Stat Methods Med Res; 2020 Feb; 29(2):508-521. PubMed ID: 30945604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective cytostatic and cytotoxic anticancer effects of bisfunctional agents: A strategy for the design of DNA binding agents.
    Spychała J
    Cancer Lett; 2009 Aug; 281(2):203-12. PubMed ID: 19303699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete event simulation applied to pediatric phase I oncology designs.
    Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
    Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
    [No Abstract]   [Full Text] [Related]  

  • 13. Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?
    Iasonos A; Gönen M; Bosl GJ
    J Clin Oncol; 2015 Jul; 33(19):2221-5. PubMed ID: 25940721
    [No Abstract]   [Full Text] [Related]  

  • 14. The rapid enrollment design for Phase I clinical trials.
    Ivanova A; Wang Y; Foster MC
    Stat Med; 2016 Jul; 35(15):2516-24. PubMed ID: 26833922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
    Markman M
    Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy with cytotoxic and cytostatic agents in brain cancer.
    Blakeley J; Grossman SA
    Handb Clin Neurol; 2012; 104():229-54. PubMed ID: 22230447
    [No Abstract]   [Full Text] [Related]  

  • 18. American Society of Clinical Oncology--41st annual meeting. Drug highlights II.
    Shah S; Yager N
    IDrugs; 2005 Jul; 8(7):534-6. PubMed ID: 15973556
    [No Abstract]   [Full Text] [Related]  

  • 19. A cytotoxic and cytostatic gold(III) corrole.
    Teo RD; Gray HB; Lim P; Termini J; Domeshek E; Gross Z
    Chem Commun (Camb); 2014 Nov; 50(89):13789-92. PubMed ID: 25252099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
    Huang B; Bycott P; Talukder E
    J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.